Metavia Doses First Patient in Higher-Dose Phase 1 Obesity Study for DA-1726
MTVA is trading near its 52-week low of $1.17 (4.3% above the low) on light trading volume (0.2× avg).
Summary
MetaVia Inc. has dosed the first patient in the higher-dose portion of its Phase 1 study for DA-1726, a GLP-1 and glucagon dual agonist targeting obesity. This represents a positive operational milestone for the company's lead pipeline candidate. While Phase 1 is an early stage of clinical development, progress in this high-interest therapeutic area is important for a micro-cap biotech, especially given the company's recent "going concern" warning and dilutive financing. Data from the Phase 1 Part 3 trial is expected in Q4 2026, which will be a key catalyst to watch.
At the time of this announcement, MTVA was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $1.17 to $23.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.